The research, conducted by Shi, J., Zhang, H., Wang, X., and colleagues and published in npj Parkinson’s Disease, addresses a long-standing puzzle in neurological research: why do Parkinson’s patients often exhibit asymmetric symptoms, and how might this reflect deeper, subtype-specific brain alterations? Traditionally, Parkinson’s disease has been clinically identified by motor symptoms such as tremors, rigidity, and bradykinesia that typically manifest asymmetrically. However, the nuances of how brain structure and function mirror these clinical asymmetries remained elusive until now.

Using high-resolution MRI modalities, including both structural and functional imaging, the research team meticulously analyzed axial brain asymmetries—the differences between corresponding regions in the left and right hemispheres—among patients classified into brain-first and body-first Parkinson’s disease subtypes. The brain-first subtype is characterized by initial neurodegeneration originating within the central nervous system, whereas the body-first subtype suggests a peripheral origin with retrograde propagation toward the brain.

The investigators applied advanced neuroimaging protocols to quantify differences in cortical thickness, subcortical volume, and resting-state functional connectivity. Their findings revealed pronounced lateralization patterns in critical regions implicated in Parkinson’s pathology, such as the substantia nigra, striatum, and various cortical motor and sensory areas. Notably, the brain-first subtype exhibited more pronounced asymmetry in the substantia nigra’s structural integrity, correlating with the typically unilateral initial motor deficits observed in these patients.

Simultaneously, functional MRI analyses exposed divergent patterns of network connectivity. Brain-first patients showed disrupted coupling between the basal ganglia and motor cortex predominantly on the affected side, aligning with the hypothesis that dopaminergic neuronal loss in these areas precipitates motor symptom onset. Conversely, individuals with body-first Parkinson’s displayed more symmetric but globally altered connectivity profiles, potentially reflecting the systemic and multisite progression of alpha-synuclein pathology inherent to their subtype.

The study also delved into axial asymmetries of cortical regions beyond the classical motor circuitry. Intriguingly, sensory integration areas and limbic structures revealed subtype-specific lateralization, which may underpin the differential presentation of non-motor symptoms across brain-first and body-first patients, including variations in cognitive impairment, mood disturbances, and autonomic dysfunction. This multidimensional approach highlights the complexity and heterogeneity of Parkinson’s disease beyond mere motor symptomatology.

Methodologically, the researchers leveraged novel analytic frameworks to map and quantify asymmetries, including voxel-based morphometry (VBM) to capture subtle regional volumetric changes, and seed-based resting-state functional connectivity analyses to interrogate functional dynamics. The integration of these techniques allowed a comprehensive portrait of how structural degeneration and network dysregulation interplay within asymmetric spatial frameworks.

From a clinical perspective, the implications are profound. Recognizing the distinct axial asymmetry signatures linked to Parkinson’s subtypes could refine diagnostic accuracy, facilitating early and subtype-specific interventions. Mapping these neuroimaging biomarkers may enable clinicians to stratify patients more effectively, tailor therapeutic strategies, and monitor disease progression with enhanced sensitivity.

Moreover, this study opens avenues for exploring the mechanistic underpinnings of Parkinson’s disease asymmetry. By correlating imaging phenotypes with molecular markers and clinical data, future research can dissect how neurodegenerative cascades evolve differently in brain-first versus body-first PD. This could unravel novel targets for disease-modifying therapies aimed at halting or reversing the spread of pathology.

Importantly, the team’s findings underscore the value of precision medicine approaches in neurodegenerative diseases. The delineation of subtype-specific brain changes through reproducible and non-invasive imaging modalities promises to bridge the gap between clinical heterogeneity and underlying biological variability—a crucial step toward personalized healthcare.

The research also contributes to ongoing debates regarding the initiation and propagation of alpha-synuclein pathology in PD. The brain-first subtype’s pronounced unilateral nigral degeneration supports models where initial CNS involvement drives disease onset. Conversely, the body-first subtype’s symmetrical connectivity disruptions lend credence to peripheral origins with systemic impact. These insights refine conceptual frameworks and may guide future neuropathological and biomarker investigations.

Furthermore, the study capitalizes on sophisticated image processing pipelines, employing automated segmentation and lateralization indices to ensure objective and reproducible measurements of asymmetry. The robust statistical design controlled for confounding factors such as age, disease duration, and medication status, enhancing the validity of the observed subtype differences.

While promising, the authors acknowledge limitations including the need for longitudinal studies to capture temporal dynamics of asymmetry evolution and the necessity to validate findings across larger, multi-center cohorts. Additionally, integrating complementary biomarkers such as cerebrospinal fluid analysis and PET imaging could enrich the characterization of subtype-specific pathophysiology.

Overall, this landmark work represents a substantive leap in delineating the neuroanatomical and functional complexities inherent to Parkinson’s disease subtypes. The elucidation of axial asymmetry patterns not only deepens scientific understanding but also charts a strategic path toward improved clinical management and therapeutic innovation.

As Parkinson’s disease continues to challenge millions worldwide, harnessing the power of neuroimaging to decode its enigmatic heterogeneity is both timely and transformative. This study exemplifies the integration of advanced imaging science with clinical neurology, positioning the field to unlock targeted, effective interventions that recognize and respect the disease’s multifaceted nature.

In conclusion, the discovery of distinct MRI-based axial asymmetry profiles that discriminate brain-first from body-first Parkinson’s disease subtypes constitutes a pivotal advance. It highlights the critical role of structural and functional brain lateralization in disease manifestation and progression. This refined neuroimaging lens will be essential for future endeavors aiming to personalize care, develop novel therapeutics, and ultimately improve outcomes for patients grappling with this complex and devastating disorder.

Subject of Research: Parkinson’s Disease Subtype Differentiation via MRI-based Structural and Functional Brain Asymmetry

Article Title: MRI structural and functional axial asymmetry in the brain-first versus body-first subtypes of Parkinson’s disease

Article References:
Shi, J., Zhang, H., Wang, X. et al. MRI structural and functional axial asymmetry in the brain-first versus body-first subtypes of Parkinson’s disease. npj Parkinsons Dis. (2025). https://doi.org/10.1038/s41531-025-01219-1

Image Credits: AI Generated

Parkinson’s disease, a debilitating neurodegenerative disorder, affects millions worldwide, characterized by the loss of dopamine-producing neurons leading to motor dysfunction and a spectrum of non-motor symptoms. Despite decades of research, teasing apart the heterogeneous nature of PD has remained a foremost challenge. The dichotomous theory posits that some patients experience an initial pathological insult in the brain (Brain-First subtype), while in others, the disease process begins in the peripheral autonomic nervous system before ascending to the brain (Body-First subtype). This crucial differentiation could tailor early intervention strategies, but has been limited by a lack of definitive biomarkers to reliably classify patients.

This new study, appearing in the prestigious journal npj Parkinson’s Disease, leverages the well-established technique of dopamine transporter single-photon emission computed tomography (DAT-SPECT). DAT-SPECT is routinely employed to visualize striatal dopaminergic integrity, serving as a surrogate marker for neurodegeneration in PD. However, solely relying on conventional DAT-SPECT metrics has not been sufficient to disentangle the proposed Brain-First versus Body-First subtypes. The innovation arises by integrating radiomics, an emerging field that extracts a large number of quantitative features from medical images using advanced computational algorithms.

Radiomics can unveil subtle patterns and textures within images imperceptible to the human eye and standard metrics. By applying radiomics-enhanced analysis to DAT-SPECT brain scans, the research team identified distinguishing signatures correlated with the two PD subtypes. These signatures capture nuanced heterogeneity in tracer uptake distribution, asymmetry, and shape characteristics of the striatal dopaminergic deficit. Such imaging phenotypes open avenues to classify individual patients more precisely and understand the underlying pathological geography.

Importantly, the study recruited a rigorously phenotyped patient cohort, encompassing newly diagnosed PD individuals along the suggested Brain-First and Body-First trajectories. The researchers validated their radiomics-based classification model against conventional visual and semi-quantitative assessments, demonstrating superior performance in discriminating subtypes. This breakthrough underscores the potential of combining conventional nuclear imaging with high-dimensional radiomic feature extraction to enhance diagnostic granularity, paving the way for personalized medicine in Parkinson’s.

Delving into the methodology, raw DAT-SPECT images underwent meticulous preprocessing to standardize spatial and intensity parameters, ensuring robustness across multi-center datasets. From the processed images, over one hundred radiomic features were extracted encompassing first-order statistics, shape, texture, and intensity-based metrics. Advanced machine learning algorithms were employed to identify the most discriminative features, culminating in an optimized classifier that markedly separated Brain-First and Body-First phenotypes with statistical rigor.

The implications of these findings extend beyond diagnosis alone. Accurately identifying PD subtypes at early stages can inform prognosis, as the Brain-First and Body-First forms differ not only in initial symptomatology but also in progression rate, cognitive involvement, and response to therapies. For instance, Body-First patients frequently experience pronounced autonomic dysfunction and REM sleep behavior disorder, whereas Brain-First patients show earlier cognitive impairment. Tailored monitoring protocols and therapeutic regimens could therefore improve patient outcomes substantially.

Moreover, this work holds promise for unraveling the pathogenic mechanisms that have long eluded the scientific community. The ability to label patients according to their disease origin supports hypotheses about distinct spreading patterns of alpha-synuclein pathology, the hallmark protein aggregate driving PD. Brain-First cases may reflect central neurodegeneration originating within substantia nigra neurons, while Body-First forms could represent peripheral-to-central propagation. Mapping these pathways with imaging aids in targeting disease-modifying treatments to the site of earliest involvement.

The radiomics-enhanced DAT-SPECT approach also advances the field of biomarker research in neurodegeneration, exemplifying how machine learning and quantitative image analysis can overcome limitations of conventional interpretation. As large international consortia collect extensive multimodal imaging and clinical datasets, such integrative analytic techniques will accelerate biomarker discovery, validation, and clinical adoption, transforming the diagnostic landscape.

Despite its promise, the research team acknowledges remaining challenges before widespread clinical translation. Larger multicenter studies are necessary to confirm replicability and generalizability across diverse populations and imaging platforms. Longitudinal investigations will elucidate how imaging phenotypes evolve over disease course and whether they predict therapeutic responses. Additionally, incorporation of complementary modalities such as MRI and peripheral biomarkers could refine subtype stratification further.

Nonetheless, this study represents a seminal leap forward in differentiating PD subtypes through sophisticated imaging analytics. By harnessing the synergy of radiomics and DAT-SPECT, clinicians now possess a powerful tool to unmask the heterogeneity underlying Parkinson’s disease, bringing precision neurology within reach. As this paradigm expands, it could catalyze new avenues for early intervention, pathophysiological understanding, and ultimately, personalized care to improve lives guarded by this relentless disorder.

The researchers envision future integration of their radiomics-based classifier into routine nuclear medicine workflows. This would enable prompt subtype identification immediately after diagnostic imaging, facilitating tailored clinical decision-making. Combined with emerging disease-modifying agents and symptomatic therapies, personalized management strategies targeting Brain-First or Body-First subgroups could revolutionize standard PD care.

In conclusion, the study published by Palermo and colleagues signals an exciting juncture in Parkinson’s research, showcasing the power of cutting-edge image analysis to clarify a major unresolved question in the field. The capacity to discriminate Brain-First from Body-First PD using conventional and radiomics-enhanced DAT-SPECT images sets the stage for fundamentally improving diagnostic accuracy, patient stratification, and targeted treatment approaches. This paradigm shift illustrates how artificial intelligence and quantitative imaging can transform clinical neuroscience, offering renewed hope in the battle against Parkinson’s disease.

Subject of Research: Differentiation of Brain-First and Body-First Parkinson’s disease subtypes using dopamine transporter SPECT imaging and radiomics.

Article Title: Discriminating between proposed Brain-First and Body-First Parkinson’s disease using conventional and radiomics-enhanced dopamine transporter SPECT image analysis.

Article References:
Palermo, G., Aghakhanyan, G., Bellini, G. et al. Discriminating between proposed Brain-First and Body-First Parkinson’s disease using conventional and radiomics-enhanced dopamine transporter SPECT image analysis. npj Parkinsons Dis. 11, 328 (2025). https://doi.org/10.1038/s41531-025-01164-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41531-025-01164-z